Possible prognostic impact of PKCι genetic variants in prostate cancer.
Molecular dynamic simulations
PKCι
Pathways
Prostate cancer
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
10 Jan 2024
10 Jan 2024
Historique:
received:
08
10
2023
accepted:
17
12
2023
medline:
11
1
2024
pubmed:
11
1
2024
entrez:
10
1
2024
Statut:
epublish
Résumé
Single nucleotide polymorphisms (SNPs) have been linked with prostate cancer (PCa) and have shown potential as prognostic markers for advanced stages. Loss of function mutations in PKCι have been linked with increased risk of malignancy by enhancing tumor cell motility and invasion. We have evaluated the impact of two coding region SNPs on the PKCι gene (PRKCI) and their prognostic potential. Genotypic association of non-synonymous PKCι SNPs rs1197750201 and rs1199520604 with PCa was determined through tetra-ARMS PCR. PKCι was docked with interacting partner Par-6 to determine the effect of these variants on PKCι binding capabilities. Molecular dynamic simulations of PKCι docked with Par-6 were performed to determine variant effects on PKCι protein interactions. The possible impact of changes in PKCι protein interactions on epithelial cell polarity was hypothesized. PKCι rs1199520604 mutant genotype TT showed association with PCa (p = 0.0055), while rs1197750201 mutant genotype AA also showed significant association with PCa (P = 0.0006). The binding interaction of PKCι with Par-6 was altered for both variants, with changes in Van der Waals energy and electrostatic energy of docked structures. Genotypic analysis of two non-synonymous PKCι variants in association with PCa prognosis was performed. Both variants in the PB1 domain showed potential as a prognostic marker for PCa. In silico analysis of the effect of the variants on PKCι protein interactions indicated they may be involved in PCa progression through aberration of epithelial cell polarity pathways.
Sections du résumé
BACKGROUND
BACKGROUND
Single nucleotide polymorphisms (SNPs) have been linked with prostate cancer (PCa) and have shown potential as prognostic markers for advanced stages. Loss of function mutations in PKCι have been linked with increased risk of malignancy by enhancing tumor cell motility and invasion. We have evaluated the impact of two coding region SNPs on the PKCι gene (PRKCI) and their prognostic potential.
METHODS
METHODS
Genotypic association of non-synonymous PKCι SNPs rs1197750201 and rs1199520604 with PCa was determined through tetra-ARMS PCR. PKCι was docked with interacting partner Par-6 to determine the effect of these variants on PKCι binding capabilities. Molecular dynamic simulations of PKCι docked with Par-6 were performed to determine variant effects on PKCι protein interactions. The possible impact of changes in PKCι protein interactions on epithelial cell polarity was hypothesized.
RESULTS
RESULTS
PKCι rs1199520604 mutant genotype TT showed association with PCa (p = 0.0055), while rs1197750201 mutant genotype AA also showed significant association with PCa (P = 0.0006). The binding interaction of PKCι with Par-6 was altered for both variants, with changes in Van der Waals energy and electrostatic energy of docked structures.
CONCLUSION
CONCLUSIONS
Genotypic analysis of two non-synonymous PKCι variants in association with PCa prognosis was performed. Both variants in the PB1 domain showed potential as a prognostic marker for PCa. In silico analysis of the effect of the variants on PKCι protein interactions indicated they may be involved in PCa progression through aberration of epithelial cell polarity pathways.
Identifiants
pubmed: 38200472
doi: 10.1186/s12935-023-03182-4
pii: 10.1186/s12935-023-03182-4
doi:
Types de publication
Journal Article
Langues
eng
Pagination
24Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2021;71(3):209–49.
pubmed: 33538338
Allemailem KS, Almatroudi A, Alrumaihi F, Almansour NM, Aldakheel FM, Rather RA, et al. Single nucleotide polymorphisms (SNPs) in prostate cancer: its implications in diagnostics and therapeutics. Am J Transl Res. 2021;13(4):3868.
pubmed: 34017579
pmcid: 8129253
Benafif S, Kote-Jarai Z, Eeles RA. A review of prostate cancer genome-wide association studies (GWAS). Cancer Epidemiol Prev Biomarkers. 2018;27(8):845–57.
doi: 10.1158/1055-9965.EPI-16-1046
Reina-Campos M, Diaz-Meco MT, Moscat J. The dual roles of the atypical protein kinase Cs in cancer. Cancer Cell. 2019;36(3):218–35.
pubmed: 31474570
pmcid: 6751000
doi: 10.1016/j.ccell.2019.07.010
Khan K, Shah H, Rehman A, Badshah Y, Ashraf NM, Shabbir M. Influence of PRKCE non-synonymous variants on protein dynamics and functionality. Human Mol Genet. 2022;31(13):2236–61.
doi: 10.1093/hmg/ddac029
Kote-Jarai Z, Al Olama AA, Giles GG, Severi G, Schleutker J, Weischer M, et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet. 2011;43(8):785–91.
pubmed: 21743467
pmcid: 3396006
doi: 10.1038/ng.882
Moscat J, Diaz-Meco MT, Albert A, Campuzano S. Cell signaling and function organized by PB1 domain interactions. Mol Cell. 2006;23(5):631–40.
pubmed: 16949360
doi: 10.1016/j.molcel.2006.08.002
Moscat J, Diaz-Meco M, Wooten M. Of the atypical PKCs, Par-4 and p62: recent understandings of the biology and pathology of a PB1-dominated complex. Cell Death Differ. 2009;16(11):1426–37.
pubmed: 19713972
doi: 10.1038/cdd.2009.119
Shah H, Khan K, Khan N, Badshah Y, Ashraf NM, Shabbir M. Impact of deleterious missense PRKCI variants on structural and functional dynamics of protein. Sci Rep. 2022;12(1):1–17.
doi: 10.1038/s41598-022-07526-4
Collins A, Ke X. Primer1: primer design web service for tetra-primer ARMS-PCR. Open Bioinform J. 2012;6:1.
doi: 10.2174/1875036201206010055
Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The human genome browser at UCSC. Genome Res. 2002;12(6):996–1006.
pubmed: 12045153
pmcid: 186604
doi: 10.1101/gr.229102
Laird PW, Zijderveld A, Linders K, Rudnicki MA, Jaenisch R, Berns A. Simplified mammalian DNA isolation procedure. Nucleic Acids Res. 1991;19(15):4293.
pubmed: 1870982
pmcid: 328579
doi: 10.1093/nar/19.15.4293
Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. The I-TASSER Suite: protein structure and function prediction. Nat Methods. 2015;12(1):7–8.
pubmed: 25549265
pmcid: 4428668
doi: 10.1038/nmeth.3213
DeLano WL. Pymol: An open-source molecular graphics tool. CCP4 Newsl Protein Crystallogr. 2002;40(1):82–92.
Messerschmidt A, Macieira S, Velarde M, Bädeker M, Benda C, Jestel A, et al. Crystal structure of the catalytic domain of human atypical protein kinase C-iota reveals interaction mode of phosphorylation site in turn motif. J Mol Biol. 2005;352(4):918–31.
pubmed: 16125198
doi: 10.1016/j.jmb.2005.07.060
Takimura T, Kamata K, Fukasawa K, Ohsawa H, Komatani H, Yoshizumi T, et al. Structures of the PKC-ι kinase domain in its ATP-bound and apo forms reveal defined structures of residues 533–551 in the C-terminal tail and their roles in ATP binding. Acta Crystallogr D Biol Crystallogr. 2010;66(5):577–83.
pubmed: 20445233
doi: 10.1107/S0907444910005639
Hirano Y, Yoshinaga S, Takeya R, Suzuki NN, Horiuchi M, Kohjima M, et al. Structure of a cell polarity regulator, a complex between atypical PKC and Par6 PB1 domains. J Biol Chem. 2005;280(10):9653–61.
pubmed: 15590654
doi: 10.1074/jbc.M409823200
Lorenz R, Bernhart SH, Siederdissen C, Tafer H, Flamm C, Stadler PF, et al. ViennaRNA Package 2.0. Algor Mol Biol. 2011;6(1):1–14.
Honorato RV, Koukos PI, Jiménez-García B, Tsaregorodtsev A, Verlato M, Giachetti A, et al. Structural biology in the clouds: the WeNMR-EOSC ecosystem. Front Mol Biosci. 2021;708:1.
Laskowski RA, Swindells MB. LigPlot+: multiple ligand–protein interaction diagrams for drug discovery. ACS Publications; 2011.
Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1:19–25.
doi: 10.1016/j.softx.2015.06.001
Bayarri G, Orozco M. 3dRS, a web-based tool to share interactive representations of 3d biomolecular structures and molecular dynamics trajectories. Front Mol Biosci. 2021;795:1.
Goldstein B, Macara IG. The PAR proteins: fundamental players in animal cell polarization. Dev Cell. 2007;13(5):609–22.
pubmed: 17981131
pmcid: 2964935
doi: 10.1016/j.devcel.2007.10.007
Smith CA, Lau KM, Rahmani Z, Dho SE, Brothers G, She YM, et al. aPKC-mediated phosphorylation regulates asymmetric membrane localization of the cell fate determinant Numb. EMBO J. 2007;26(2):468–80.
pubmed: 17203073
pmcid: 1783459
doi: 10.1038/sj.emboj.7601495
Khan N, Khan K, Badshah Y, Trembley JH, Ashraf NM, Shabbir M, et al. Investigating pathogenic SNP of PKCι in HCV-induced hepatocellular carcinoma. Sci Rep. 2023;13(1):12504.
pubmed: 37532886
pmcid: 10397245
doi: 10.1038/s41598-023-39804-0
Shah H, Khan K, Khan N, Badshah Y, Ashraf NM, Shabbir M. Impact of deleterious missense PRKCI variants on structural and functional dynamics of protein. Sci Rep. 2022;12(1):3781.
pubmed: 35260606
pmcid: 8904829
doi: 10.1038/s41598-022-07526-4
Shah H, Khan K, Badshah Y, Trembley JH, Ashraf NM, Shabbir M, et al. Association of PKCi variant and its gene expression with breast cancer prognosis. 2022.
Wu Z, Huang C, Li R, Li H, Lu H, Lin Z. PRKCI mediates radiosensitivity via the hedgehog/GLI1 pathway in cervical cancer. Front Oncol. 2022;12: 887139.
pubmed: 35785194
pmcid: 9243290
doi: 10.3389/fonc.2022.887139
Linch M, Sanz-Garcia M, Soriano E, Zhang Y, Riou P, Rosse C, et al. A cancer-associated mutation in atypical protein kinase Cι occurs in a substrate-specific recruitment motif. Sci Signal. 2013;6(293):ra82.
pubmed: 24045153
doi: 10.1126/scisignal.2004068
Antal CE, Hudson AM, Kang E, Zanca C, Wirth C, Stephenson NL, et al. Cancer-associated protein kinase C mutations reveal kinase’s role as tumor suppressor. Cell. 2015;160(3):489–502.
pubmed: 25619690
pmcid: 4313737
doi: 10.1016/j.cell.2015.01.001
Newton AC, Brognard J. Reversing the paradigm: protein kinase C as a tumor suppressor. Trends Pharmacol Sci. 2017;38(5):438–47.
pubmed: 28283201
pmcid: 5403564
doi: 10.1016/j.tips.2017.02.002
Ishiguro H, Akimoto K, Nagashima Y, Kojima Y, Sasaki T, Ishiguro-Imagawa Y, et al. aPKCλ/ι promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. Proc Natl Acad Sci. 2009;106(38):16369–74.
pubmed: 19805306
pmcid: 2752573
doi: 10.1073/pnas.0907044106
Ratnayake WS, Apostolatos CA, Breedy S, Dennison CL, Hill R, Acevedo-Duncan M. Atypical PKCs activate Vimentin to facilitate prostate cancer cell motility and invasion. Cell Adh Migr. 2021;15(1):37–57.
pubmed: 33525953
pmcid: 7889213
doi: 10.1080/19336918.2021.1882782
Knoblich JA. Asymmetric cell division: recent developments and their implications for tumour biology. Nat Rev Mol Cell Biol. 2010;11(12):849–60.
pubmed: 21102610
pmcid: 3941022
doi: 10.1038/nrm3010
Shin K, Fogg VC, Margolis B. Tight junctions and cell polarity. Annu Rev Cell Dev Biol. 2006;22:207–35.
pubmed: 16771626
doi: 10.1146/annurev.cellbio.22.010305.104219
Sotriffer CA, Krämer O, Klebe G. Probing flexibility and “induced-fit” phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations. Proteins. 2004;56(1):52–66.
pubmed: 15162486
doi: 10.1002/prot.20021
Dong Y-W, Liao M-l, Meng X-l, Somero GN. Structural flexibility and protein adaptation to temperature: molecular dynamics analysis of malate dehydrogenases of marine molluscs. Proc Natl Acad Sci. 2018;115(6):1274–9.
Duchardt-Ferner E, Gottstein-Schmidtke SR, Weigand JE, Ohlenschläger O, Wurm JP, Hammann C, et al. What a difference an OH makes: conformational dynamics as the basis for the ligand specificity of the neomycin-sensing riboswitch. Angew Chem Int Ed. 2016;55(4):1527–30.
doi: 10.1002/anie.201507365
Minton AP. Models for excluded volume interaction between an unfolded protein and rigid macromolecular cosolutes: macromolecular crowding and protein stability revisited. Biophys J. 2005;88(2):971–85.
pubmed: 15596487
doi: 10.1529/biophysj.104.050351
Zhao Y, Cai C, Zhang M, Shi L, Wang J, Zhang H, et al. Ephrin-A2 promotes prostate cancer metastasis by enhancing angiogenesis and promoting EMT. J Cancer Res Clin Oncol. 2021;147:2013–23.
pubmed: 33772606
doi: 10.1007/s00432-021-03618-2
Jung H-Y, Fattet L, Tsai JH, Kajimoto T, Chang Q, Newton AC, et al. Apical–basal polarity inhibits epithelial–mesenchymal transition and tumour metastasis by PAR-complex-mediated SNAI1 degradation. Nat Cell Biol. 2019;21(3):359–71.
pubmed: 30804505
pmcid: 6546105
doi: 10.1038/s41556-019-0291-8
Singh D, Deshmukh RK, Das A. SNAI1-mediated transcriptional regulation of epithelial-to-mesenchymal transition genes in breast cancer stem cells. Cell Signal. 2021;87: 110151.
pubmed: 34537302
doi: 10.1016/j.cellsig.2021.110151
Faure G, Ogurtsov AY, Shabalina SA, Koonin EV. Role of mRNA structure in the control of protein folding. Nucleic Acids Res. 2016;44(22):10898–911.
pubmed: 27466388
pmcid: 5159526
doi: 10.1093/nar/gkw671
Faure G, Ogurtsov AY, Shabalina SA, Koonin EV. Adaptation of mRNA structure to control protein folding. RNA Biol. 2017;14(12):1649–54.
pubmed: 28722509
pmcid: 5731814
doi: 10.1080/15476286.2017.1349047
Rodnina MV. The ribosome in action: tuning of translational efficiency and protein folding. Protein Sci. 2016;25(8):1390–406.
pubmed: 27198711
pmcid: 4972197
doi: 10.1002/pro.2950
Morganti S, Tarantino P, Ferraro E, D’Amico P, Duso BA, Curigliano G. Next generation sequencing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in cancer. Transl Res Onco-omics Appl Era Cancer Pers Genom. 2019;1:9–30.
doi: 10.1007/978-3-030-24100-1_2
Porras A, Williams FE, Basuroy T. Cell maintenance and the establishment of cell polarity involve complicated interactions among multiple protein complexes as well as the regulation of different signaling pathways. As an important cell polarity protein, Par3 is evolutionarily conserved and involved in tight junction formation as well as tumorigenesis. In this review, we aimed to explore the function of Par3 in tumorigenesis. Research has shown that Par3 exhibits dual. Rev Mol Cell Oncol. 2023:158.